348 related articles for article (PubMed ID: 24929164)
1. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
[TBL] [Abstract][Full Text] [Related]
3. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
4. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
5. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Sato T; Hayakawa K; Tomita N; Noda M; Kamikonya N; Watanabe T; Kato D; Sakai Y; Hiraoka M; Shimada M; Ikushima H; Baba H; Oya N; Oya M; Nemoto-Murofushi K; Takeuchi M; Watanabe M
Radiother Oncol; 2016 Aug; 120(2):222-7. PubMed ID: 27317556
[TBL] [Abstract][Full Text] [Related]
7. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
8. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
9. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
[TBL] [Abstract][Full Text] [Related]
13. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
14. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
Mohiuddin M; Paulus R; Mitchell E; Hanna N; Yuen A; Nichols R; Yalavarthi S; Hayostek C; Willett C
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):523-8. PubMed ID: 23545284
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
19. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Ishii Y; Hasegawa H; Endo T; Okabayashi K; Ochiai H; Moritani K; Watanabe M; Kitagawa Y
Eur J Surg Oncol; 2010 Nov; 36(11):1061-5. PubMed ID: 20538422
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
Kuriu Y; Kokuba Y; Murayama Y; Komatsu S; Shiozaki A; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1951-3. PubMed ID: 23267940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
